PTC Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
PTC Therapeutics, Inc. (PTCT) had Debt Securities, Available-for-sale, Unrealized Loss Position of $1.07 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-07-30
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $1.07B.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $644.53M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $95.37M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $134.35M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $1.07B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $644.53M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $95.37M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $134.35M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $508.20M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $125.02M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $89.36M 10-K · filed 2026-02-19 |
| 2024-09-30 | $14.98M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $293.89M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $113.55M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $46.09M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.63M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $1.60M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $10.25M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $10.19M 10-K · filed 2024-02-29 |
| 2022-09-30 | $71.00M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $149.97M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $232.79M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $261.79M 10-K · filed 2023-02-21 |
| 2021-09-30 | $98.70M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $117.89M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $266.05M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $260.97M 10-K · filed 2022-02-22 |
| 2020-09-30 | $151.25M 10-Q · filed 2020-10-29 |
| 2019-12-31 | $95.99M 10-K · filed 2021-02-25 |
| 2018-12-31 | $26.31M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |